Collaboration in health technology assessment (Eunethta joint action, 2010-2012): Four case studies

International Journal of Technology Assessment in Health Care

Volumn 29, Issue 3, 2013, Pages 323-330

  Huić, Mirjana ^a   Nachtnebel, Anna ^b   Zechmeister, Ingrid ^b   Pasternak, Iris ^c   Wild, Claudia ^b  

^a Agency for Quality and Accreditation in Health Care   (Croatia)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Cross border healthcare directive; EUnetHTA JA; Health technology assessment; International collaboration

Indexed keywords

ASSESSMENT METHODOLOGIES; CROSS-BORDER; DEGREE OF COMMITMENT; ENGLISH LANGUAGES; EUNETHTA JA; HEALTH TECHNOLOGY ASSESSMENTS; INTERNATIONAL COLLABORATIONS; RETROSPECTIVE ANALYSIS;

HEALTH; INTERNATIONAL COOPERATION; PROJECT MANAGEMENT; TECHNOLOGY;

LIFE CYCLE;

BEVACIZUMAB; CABAZITAXEL; RANIBIZUMAB;

ARTICLE; CANCER CHEMOTHERAPY; CARPAL TUNNEL SYNDROME; CASTRATION RESISTANT PROSTATE CANCER; CONSERVATIVE TREATMENT; DECISION SUPPORT SYSTEM; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE; HOSPITAL; HOSPITAL MANAGEMENT; HUMAN; INFORMATION SYSTEM; LANGUAGE; RETROSPECTIVE STUDY; TECHNOLOGY;

EUROPEAN UNION; INTERNATIONAL COOPERATION; ORGANIZATIONAL CASE STUDIES; RETROSPECTIVE STUDIES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84880437349     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462313000305     Document Type: Article

References (29)

1. M̈akel̈a M, Rośen M, Jamtvedt G, Kristensen FB, Mørland B. Cooperation is strength: Joint achievements of the Nordic HTA centers. Michael. 2012;9:137-146.
2. Sampietro-Colom L, Semberg V, Dolors Estrada M, et al. European joint assessments and coordination of findings and resources. Int J Technol Assess Health Care. 2002;8:321-360.
3. Kristensen FB. Development of European HTA: from Vision to EUnetHTA. Michael. 2012;9:147-156.
4. Hailey D, Marshall D, Sampietro-Colom L, et al. International collaboration in health technology assessment: a study of technologies used in management of osteoporosis. Health Policy. 1998;43:233-241.
5. Drummond MF, Schwartz JS, Jonsson B, et al. Key principles for the improved conduct of health technology assessment for resource allocation decisions. Int J Technol Assess Health Care. 2008;24:244-258.
6. Rottingen JA, Gerhardus A, Garrido MV. Future challenges for HTA in Europe. In: Garrido MV, Kristensen FB, Nielsen CP, Busse R, eds. Health technology assessment and health policy-making in Europe. Current status, challenges and potential. Observatory Studies Series No14, World Health Organization 2008, on behalf of the European Observatory on Health Systems and Policies.
7. Garrido MV, Busse R. Health technology assessment. An introduction to objectives, role of evidence, and structure in Europe. World Health Organization 2005, on behalf of the European Observatory on Health Systems and Policies.
8. Kristensen FB, Gerhardus A. Health technology assessments: what do differing conclusions tell us? BMJ. 2010;341:c5236
9. Kristensen FB, Nielsen CP, Chase D, Lampe K, Lee-Robin SH, M̈akel̈a M. What is health technology assessment? In: Velasco-Garrido M, Kristensen FB, Palmhøj Nielsen C, Busse R, eds. Health technology assessment and health policy-making in Europe-Current status, challenges and potential. Copenhagen: WHO Regional Office for Europe: 2008:53-78.
10. Henshall C, Mardhani-Bayne L, Fronsdal KB, Klemp M. On behalf of the HTAi Policy Forum. Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities. Int J Technol Assess Health Care. 2011;27:253-260.
11. Kristensen FB, Lampe K, Chase D, et al. Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA. Int J Technol Assess Health Care. 2009; 25(Suppl 2):68-73.
12. Lampe K, M̈akel̈a M, Garrido MV, et al. The HTA Core Model-A novel method for producing and reporting health technology assessments. Int J Technol Assess Health Care. 2009;25(Suppl 2):1-8.
13. Wild C, Hinterreiter G, Warmuth M, Erd̈os J. POP db: The EUnetHTA planned and ongoing projects database: Content and use. Poster at EUnetHTA conference in Gdansk/Poland, 8-9 December 2011.
14. Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients' rights in cross-border healthcare. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ: L:2011:088:0045:0065: EN:PDF. (accessed April 28, 2012).
15. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updatedMarch 2011). The Cochrane Collaboration, 2011. www.cochrane-handbook.org (accessed March 12, 2011).
16. Higgins J, Altman DG, Gotzsche PC, et al. The Cochrane Collaborations tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
17. Oxford Centre for Evidence-based Medicine. Levels of Evidence 2009. http://www.cebm.net/index.aspx?o=1025 (accessed February 10, 2011).
18. Guyatt G, Oxman AD, Akl E, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383-394.
19. Ludwig Boltzmann Institute for Health Technology Assessment. Horizon scanning in oncology-Part II: From pilot to routine. 2008. http://hta.lbg.ac.at/ en/projekt-detail.php?iMenuID=80&iProjectID=30 (accessed May 2, 2012).
20. Nachtnebel A. Second-line chemotherapy with cabazitaxel (JevtanaR-) for the treatment of castration-resistant metastatic prostate cancer. DSD: Horizon Scanning in Oncology. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment: 16; 2011.
21. Nachtnebel A, Sotti G, Vitale A, Perrini MR. Selective internal radiotherapy using yttrium-90 microspheres for primary and secondary liver malignancies. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; 2011.
22. Agency for Quality and Accreditation in Health Care, Department for Development, Research and Health Technology Assessment. The Croatian guideline for health technology assessment process and reporting, 1st ed. Zagreb. http://www.aaz.hr/main.php?ID = 21. (accessed February 2011).
23. Zechmeister-Koss I, Huíc M. Vascular endothelial growth factor inhibitors (anti-VEGF) for diabetic macular oedema. Decision support document Nr. 43. Wien; Zagreb: Ludwig Boltzmann Institut f̈ur Health Technology Assessment; Agencija za kvalitetu i akreditaciju u zdravstvu; 2011.
24. Zechmeister-Koss I, Huíc M. Anti-Vascular-Endothelial-Growth- Factor (Anti-VEGF) bei diabetischem Makuläodem. Systematischer Review. Decision support documentNr. 43.Wien,Zagreb: Ludwig Boltzmann Institut f̈ur Health Technology Assessment; Agencija za kvalitetu i akreditaciju u zdravstvu; 2011.
25. Zechmeister-Koss I, HuícM.Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. Br J Ophthalmol. 2012;96:167-178.
26. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.
27. The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument. www.agreecollaboration.org. (accessed December 18, 2011).
28. Sorenson C. The role of HTA in coverage and pricing decision: A crosscountry comparison. Euro Observer. 2009;11:1-12.
29. Kleijnen S, George E,Goulden S, et al. Relative EffectivenessAssessment of Pharmaceuticals: Similarities andDifferences in 29 Jurisdictions. Value Health. 2012;15:954-960.